BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 18182670)

  • 21. [Economic evaluation of prophylaxis with recombinant granulopoiesis stimulating factor].
    Antoñanzas F; Rovira J; Garuz R; Antón F
    Med Clin (Barc); 1992 Nov; 99(18):685-9. PubMed ID: 1282638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evidence-based management of neutropenia and fever].
    Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
    Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
    Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
    Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
    Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
    Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of primary prophylaxis on febrile neutropenia within community practices in the US.
    Hershman D; Hurley D; Wong M; Morrison VA; Malin JL
    J Med Econ; 2009 Sep; 12(3):203-10. PubMed ID: 19723018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
    Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
    Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Role of hematopoietic growth factors in bronchial cancerology].
    Lemarié E; Milleron B
    Rev Mal Respir; 1995; 12(5):429-34. PubMed ID: 8560073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.